Top Story

OCT angiography quantitates differences in lesion responses to anti-VEGF therapy

OCT angiography quantitates differences in lesion responses to anti-VEGF therapy
May 25, 2016

COLORADO SPRINGS, Colo. — Type 1 neovascular lesions are large, mature and resistant to anti-VEGF therapy, whereas type 3 lesions are small capillary tufts that are highly responsive to just one anti-VEGF injection, according to a study presented here.

Using OCT angiography, David Sarraf, MD, and colleagues looked at the quantitative and qualitative effects of anti-VEGF therapy in both types of lesions in cases of age-related macular degeneration.

Meeting News CoverageFrom OSN Europe

Progressive IOL for mini incision shows good preliminary study results

May 25, 2016
MILAN — A new progressive IOL for a mini incision provides optimal vision at all distances, with no halos and a minimal amount of glare, according to the…

BLOG: Welcome new rhexis makers, but don’t trade in your femto

May 25, 2016
In the cover story of this issue of OSN, we discuss new alternate devices that can assist in capsulotomy creation. Femtosecond laser surgery in the U.S. grew to 9.5% of…
Meeting News CoverageVideo

VIDEO: Surgeon recommends screening patients for ocular surface issues before cataract surgery

May 25, 2016
NEW ORLEANS — At the American Society of Cataract and Refractive Surgery meeting, Sumitra Khandelwal, MD, discusses how she uses TearLab's osmolarity test in her…
In the Journals

Physicians call for universal, single-payer health care system

May 25, 2016
In an editorial published in the American Journal of Public Health, researchers outlined a proposal to overhaul the nation’s current health care system and…
More News Headlines »
Clinical Science

Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants

Ophthalmic Surgery, Lasers and Imaging Retina, May 2016, Volume 47 Issue 5
To evaluate glaucomatous changes in patients with diabetic macular edema (DME) treated with intravitreal implants…
More »

Clinical Trials in Diabetic Retinopathy

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Highlights from ASCRS

Highlights from ASCRS

Meeting News Coverage

VIDEO: Reverse side cuts with femtosecond laser enable better self-sealing of primary incision during cataract surgery

May 23, 2016
More »